11 – 20 of 20
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- next »
- 2022
-
Mark
Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson’s disease
(
- Contribution to journal › Article
-
Mark
High risk of developing dementia in Parkinson’s disease : a Swedish registry-based study
(
- Contribution to journal › Article
- 2021
-
Mark
Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson’s Disease : A Swedish Register-Based Study in 1823 Observations
(
- Contribution to journal › Article
-
Mark
Parkinson’s disease in Sweden—resource use and costs by severity
(
- Contribution to journal › Article
-
Mark
Swedish guidelines for device-aided therapies in Parkinson's disease —Economic evaluation and implementation
(
- Contribution to journal › Article
- 2016
-
Mark
Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice.
2016) In BioDrugs(
- Contribution to journal › Article
- 2015
-
Mark
Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
(
- Contribution to journal › Article
-
Mark
Resource Use in Patients with Psoriasis After the Introduction of Biologics in Sweden
(
- Contribution to journal › Article
- 2012
-
Mark
Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice
(
- Contribution to journal › Article
- 2010
-
Mark
A Cost-effectiveness Analysis of Diagnostic Algorithms of Deep Vein Thrombosis at the Emergency Department.
(
- Contribution to journal › Article
- « previous
- 1
- 2
- next »